세계의 유잉육종 시장 : 출시 약품과 파이프라인 약품 평가, 임상시험, 경쟁 구도

Ewing Sarcoma Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

US $ 3,495 ￦ 5,056,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,990 ￦ 10,113,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,485 ￦ 15,170,000

PDF (Global License)

PDF 보고서를 동일 기업(해외)의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다

한글목차

세계의 유잉육종 시장에 대해 조사분석했으며, 질환 상황, 출시 약품과 파이프라인 약품 평가, 현재와 향후 경쟁 구도 등을 제공하고 있습니다.

목차

제1장 서문

제2장 주요 조사 결과

제3장 질환 상황

• 질환의 개요
• 역학의 개요
• 치료의 개요

제4장 출시 약품 평가

• 주요 출시 약품
• 개요 : 작용기서별
• 개요 : 투여 경로별
• 출시 약품 개요와 판매 예측

제5장 가격결정과 상환 평가

• 연간 치료비
• 가격결정과 상환까지의 시간

제6장 파이프라인 약품 평가

• 단계 3 파이프라인 약품
• 개요 : 개발 단계별
• 개요 : 분자 유형별
• 개요 : 작용기서별
• 개요 : 투여 경로별
• 약품 고유 단계 이동 성공률(PTSR)과 승인 가능성(LoA)
• 치료 영역과 적응증 고유 PTSR과 LoA

제7장 임상시험 평가

• 과거의 개요
• 개요 : 단계별
• 개요 : 현황별
• 개요 : 진행중·계획중인 시험의 단계별
• 가상 컴포넌트를 사용한 시험
• 지역적 개요
• 단일국·다국간 시험 : 지역별
• 내역 : 상위 20 스폰서와 단계별
• 내역 : 상위 20 스폰서 현황별
• 개요 : 엔드포인트 현황별
• 개요 : 인종·민족별
• 등록 데이터
• 시험 시설 상위 20개국
• 세계의 상위 20 시설
• 실현 가능성 분석 - 지역적 개요
• 실현 가능성 분석 - 벤치마크 모델

제8장 거래 상황

• 합병, 인수, 전략적 제휴 : 지역별
• 최근 합병, 인수, 전략적 제휴

제9장 상업적 평가

• 주요 시장 기업

제10장 향후 시장 촉매

제11장 부록

KSA

영문 목차

영문목차

Abstract

This reports provides a data-driven overview of the current and future competitive landscape in Ewing Sarcoma therapeutics.

• There will be only 9,457 diagnosed prevalent cases of ES in 2023 in the 16 countries covered in GlobalData's epidemiology forecast for ES.
• There are currently 11 marketed drugs for ES, the majority of which are DNA synthesis inhibitors.
• R&D activity in ES is very strong in mid-stage, with 32 drugs in Phase II of development.
• Clinical trial activity in ES was substantial during the past 10 years with 193 trials conducted overall.
• Partnerships were the most common deal type executed globally in the ES space.

Scope

GlobalData's Ewing Sarcoma: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Ewing Sarcoma market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Ewing Sarcoma market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Table of Contents

1 Preface

• 1.1 Contents
• 1.2 Report Scope
• 1.3 List of Tables and Figures
• 1.4 Abbreviations

2 Key Findings

3 Disease Landscape

• 3.1 Disease Overview
• 3.2 Epidemiology Overview
• 3.3 Treatment Overview

4 Marketed Drugs Assessment

• 4.1 Leading Marketed Drugs
• 4.2 Overview by Mechanism of Action
• 4.3 Overview by Route of Administration
• 4.4 Marketed Drugs Profiles and Sales Forecasts

5 Pricing and Reimbursement Assessment

• 5.1 Annual Therapy Cost
• 5.2 Time to Pricing and Reimbursement

6 Pipeline Drugs Assessment

• 6.1 Phase III Pipeline Drugs
• 6.2 Overview by Development Stage
• 6.3 Overview by Molecule Type
• 6.4 Overview by Mechanism of Action
• 6.5 Overview by Route of Administration
• 6.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
• 6.7 Therapy Area and Indication-specific PTSR and LoA

7 Clinical Trials Assessment

• 7.1 Historical Overview
• 7.2 Overview by Phase
• 7.3 Overview by Status
• 7.4 Overview by Phase for Ongoing and Planned Trials
• 7.5 Trials with Virtual Components
• 7.6 Geographic Overview
• 7.7 Single-Country and Multinational Trials by Region
• 7.8 Top 20 Sponsors with Breakdown by Phase
• 7.9 Top 20 Sponsors with Breakdown by Status
• 7.10 Overview by Endpoint Status
• 7.11 Overview by Race and Ethnicity
• 7.12 Enrollment Data
• 7.13 Top 20 countries for Trial Sites
• 7.14 Top 20 Sites Globally
• 7.15 Feasibility Analysis - Geographic Overview
• 7.16 Feasibility Analysis - Benchmark Models

8 Deals Landscape

• 8.1 Mergers, Acquisitions, and Strategic Alliances by Region
• 8.2 Recent Mergers, Acquisitions, and Strategic Alliances

9 Commercial Assessment

• 9.1 Key Market Players

10 Future Market Catalysts

11 Appendix

• 11.1 Methodology
• 11.2 Methodology - Sales Forecast
• 11.3 Methodology - Pricing and Reimbursement
• 11.4 Methodology - PTSR and LoA Analysis
• 11.5 About the Authors
• 11.6 Contact Us
• 11.7 Disclaimer

관련자료